drugset / Trial / NCT07587008

Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteers

NCT07587008

Phase 1 Active not recruiting 12 enrolled AbbVie
RandomizedCrossoverOpen-labelBasic science

Summary

The objective of this study is to evaluate the pharmacokinetics (PK) and relative bioavailability of emraclidine following single oral administration of different immediate-release (IR) tablet formulations in healthy adult participants.

Timeline

Start
2026-05-12
Primary completion
2026-07
Completion
2026-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Emraclidine Small molecule Oral

Indications

No indication recorded.